The American Journal of Medicine
Volume 123, Issue 2 , Pages 103-110 , February 2010

The Thrombin Hypothesis in ACS: A Disappointing Disconnect between Bench Data and Bedside Clinical Trials

  • Marc Cohen, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Marc Cohen, MD, Division of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Avenue at Osborne Terrace, Newark, NJ 07112

References 

  1. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina (A meta-analysis). JAMA. 1996;276:811–815
  2. Murphy SA, Gibson CM, Morrow DA, et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J. 2007;28:2077–2086
  3. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295:1519–1530
  4. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203–2216
  5. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218–2230
  6. Kokolis S, Cavusoglu E, Clark LT, Marmur JD. Anticoagulation strategies for patients undergoing percutaneous coronary intervention: unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors. Prog Cardiovasc Dis. 2004;46:506–523
  7. Spencer FA, Ball SP, Zhang Q, et al. Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization. J Thromb Thrombolysis. 2000;9:223–228
  8. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385–391
  9. Kumar R, Béguin S, Hemker HC. The influence of fibrinogen and fibrin on thrombin generation--evidence for feedback activation of the clotting system by clot bound thrombin. Thromb Haemost. 1994;72:713–721
  10. Gurm HS, Bhatt DL. Thrombin, an ideal target for pharmacological inhibition: a review of direct thrombin inhibitors. Am Heart J. 2005;149(1 Suppl):S43–S53
  11. Alexander J. Safety of the factor Xa inhibitor, Apixaban, in combination with antiplatelet therapy after acute coronary syndrome: results of the APPRAISE-1 dose guiding trial. Late-breaking abstract. European Society of Cardiology (ESC) Congress, 30 Aug 2008-03 Sep 2008, Munich, Germany.
  12. Cohen M, Bhatt DL, Alexander JH, et al. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation. 2007;115:2642–2651
  13. Weitz JI, Buller HR. Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation. 2002;105:1004–1011
  14. Weitz JI, Crowther M. Direct thrombin inhibitors. Thromb Res. 2002;106:V275–V284
  15. Frenkel EP, Shen YM, Haley BB. The direct thrombin inhibitors: their role and use for rational anticoagulation. Hematol Oncol Clin North Am. 2005;19:119–145
  16. Krupski WC, Bass A, Kelly AB, et al. Heparin-resistant thrombus formation by endovascular stents in baboons (Interruption by a synthetic antithrombin). Circulation. 1990;82:570–577
  17. Fuster V, Badimon L, Badimon JJ, et al. The porcine model for the understanding of thrombosis and atherogenesis. Mayo Clinic Proc. 1991;66:818–831
  18. Meyer BJ, Badimon JJ, Chesebro JH, et al. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin. Circulation. 1998;97:681–685
  19. Wienen W, Stassen JM, Priepke H, et al. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost. 2007;98:333–338
  20. Wienen W, Stassen JM, Priepke H, et al. Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis. J Thromb Haemost. 2007;5:1237–1242
  21. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin. Thromb Haemost. 1994;72:381–386
  22. Van Aken H, Bode C, Darius H, et al. Anticoagulation: the present and future. Clin Appl Thromb Hemost. 2001;7:195–204
  23. Walenga JM. An overview of the direct thrombin inhibitor argatroban. Pathophysiol Haemost Thromb. 2002;32(Suppl 3):9–14
  24. Matsuo T, Koide M, Kario K. Development of argatroban, a direct thrombin inhibitor, and its clinical application. Semin Thromb Hemost. 1997;23:517–522
  25. Jang IK, Brown DF, Giugliano RP, et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. J Am Coll Cardiol. 1999;33:1879–1885
  26. Behar S, Hod H, Kaplinsky E. Argatroban versus heparin as adjuvant therapy to thrombolysis for acute myocardial infarction: safety considerations—ARGAMI-2 Study. Circulation. 1998;98(Suppl 17):I453–I454
  27. Andersen K, Dellborg M. Heparin is more effective than inogatran, a low-molecular-weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease (Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group). Am J Cardiol. 1998;81:939–944
  28. Fung AY, Lorch G, Cambier PA, et al. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction (ESCALAT Investigators). Am Heart J. 1999;138:696–704
  29. Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet. 2003;362:789–797
  30. Petersen P, Grind M Adler J for the SPORTIF II Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation (SPORTIF II: a dose-guiding, tolerability, and safety study). J Am Coll Cardiol. 2003;41:1445–1451
  31. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes (The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators). N Engl J Med. 1996;335:775–782
  32. Antman EM. Hirudin in acute myocardial infarction (Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial). Circulation. 1996;94:911–921
  33. Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet. 2002;359:294–302
  34. Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol. 1998;82:12P–18P
  35. Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, doses, and gender. Clin Pharmacol Ther. 2002;71:433–439
  36. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina (Hirulog Angioplasty Study Investigators). N Engl J Med. 1995;333:764–769
  37. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853–863
  38. Stone GW, Ware JH, Bertrand ME, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA. 2007;298:2497–2506
  39. White H Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet. 2001;358:1855–1863
  40. Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med. 2008;359:688–696
  41. Yusuf S, Mehta SR, Chrolavicius S, et al. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464–1476
  42. Rebello SS, Bentley RG, Morgan SR, et al. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis. Br J Pharmacol. 2001;133:1190–1198
  43. Hinder M, Frick A, Jordaan P, et al. Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease. Clin Pharmacol Ther. 2006;80:691–702
  44. Study of otamixaban versus unfractionated heparin and eptifibatide in non-ST elevation acute coronary syndrome (SEPIA-ACS 1). ClinicalTrials.gov identifier: NCT00317395. Available at: www.clinicaltrials.gov.
  45. Gibson CM, Mega JL, Hammett CJ, et al. Randomized comparison of rivaroxaban, an oral direct factor Xa inhibitor, with placebo in patients with acute coronary syndromes: the ATLAS ACS-TIMI 46 trial. Circulation. 2008;118:2309–2317
  46. Shimbo D, Osende J, Chen J, et al. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin. Thromb Haemost. 2002;88:733–738
  47. Karnicki K, McBane RD, Miller RS, et al. Inhibition and reversal of platelet-rich arterial thrombus in vivo: direct vs. indirect factor Xa inhibition. J Thromb Haemost. 2004;2:2162–2169
  48. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group). N Engl J Med. 1997;337:447–452
  49. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45–54
  50. White HD, Kleiman NS, Mahaffey KW, et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J. 2006;152:1042–1050
  51. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354:1477–1488
  52. Cheng S, Morrow DA, Sloan S, et al. Predictors of excessive anticoagulation with unfractionated heparin in STEMI. J Am Coll Cardiol. 2008;51(Suppl 1):A204
  53. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol. 2007;49:1362–1368
  54. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction (Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial). Circulation. 1999;100:1593–1601

 Funding: Editorial/writing support for the preparation of this manuscript was funded by sanofi-aventis. The author, however, was fully responsible for all content and received no financial support or other form of compensation related to the development of the article.

 Conflict of Interest: The author received grant support from Aventis Pharmaceuticals, consulting fees from sanofi-aventis and AstraZeneca, and lecture fees from sanofi-aventis, Merck, and Schering.

 Authorship: Author had access to the data and a role in writing the manuscript.

PII: S0002-9343(09)00772-4

doi: 10.1016/j.amjmed.2009.09.001

The American Journal of Medicine
Volume 123, Issue 2 , Pages 103-110 , February 2010

Article Tools

* Image Usage & Resolution